An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
An Open-label, Non-interventional, Single-group Follow-up Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Adult Patients with Relapsed or Refractory Forms of B-cell Lymphoproliferative Disorders
Sponsor: National Research Center for Hematology, Russia
Listed as NCT06721598, this observational or N/A phase trial focuses on Acute Lymphoblastic Leukemia ALL and Non-Hodgkin Lymphoma, B-cell and remains actively recruiting participants. Sponsored by National Research Center for Hematology, Russia, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Sep 2025 — Present [monthly]
Not Yet Recruiting
-
Jan 2025 — Sep 2025 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Research Center for Hematology, Russia
For direct contact, visit the study record on ClinicalTrials.gov .